Atrium Therapeutics, Inc. Common Stock (RNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $162.00M
Last updated: Nov 17, 2026 at 11:06 AM ET
Atrium Therapeutics, Inc. Common Stock (RNA) Competitors
The companies most similar to Atrium Therapeutics, Inc. Common Stock are Invivyd (IVVD), Anixa Biosciences (ANIX) and Codexis (CDXS). By market cap, Atrium Therapeutics, Inc. Common Stock ranks 6th of the 13 companies on this page; SAB Biotherapeutics (SABS) is the largest at $266.66M.
Peer Comparison
RNA's ROIC of -44.5% is above the peer median of -184.6%, and its revenue growth of 24.2% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Codexis Inc (CDXS) | $127.13M | N/A | N/A | -21.8% | N/A | 124.0% | 0.00% |
| SAB Biotherapeutics Inc (SABS) | $266.66M | N/A | N/A | 0.0% | N/A | -62.4% | 0.00% |
| Palisade Bio Inc (PALI) | $201.01M | N/A | 436.8x | 0.0% | N/A | 0.0% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| PolyPid (PYPD) | $132.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| OUTLOOK THERAPEUTICS INC (OTLK) | $100.54M | N/A | N/A | 0.0% | -776.9% | -99.4% | 0.00% |
| Sutro Biopharma (STRO) | $163.03M | N/A | 3.4x | 0.0% | N/A | -6.1% | 0.00% |
| Armata Pharmaceuticals Inc (ARMP) | $143.94M | N/A | 14.7x | 0.0% | -184.6% | 173.6% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Peer median | $153.26M | N/A | 14.7x | 0.0% | -184.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Atrium Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Codexis Inc (CDXS) | Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California. | CDXS competitors |
| SAB Biotherapeutics Inc (SABS) | SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. | SABS competitors |
| Palisade Bio Inc (PALI) | Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. | PALI competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| PolyPid (PYPD) | PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)... | PYPD competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| OUTLOOK THERAPEUTICS INC (OTLK) | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic... | OTLK competitors |
| Sutro Biopharma (STRO) | Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. | STRO competitors |
| Armata Pharmaceuticals Inc (ARMP) | Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment... | ARMP competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
Frequently Asked Questions About RNA
Who are Atrium Therapeutics, Inc. Common Stock's main competitors?
The companies most similar to Atrium Therapeutics, Inc. Common Stock include Invivyd (IVVD), Anixa Biosciences (ANIX), Codexis (CDXS), SAB Biotherapeutics (SABS) and Palisade Bio (PALI), listed from the closest match.
Who is Atrium Therapeutics, Inc. Common Stock's biggest competitor?
SAB Biotherapeutics (SABS) is the largest of the similar companies at $266.66M; Invivyd (IVVD) is the closest match by business profile, size, sector and industry.
How does RNA stock compare with its competitors?
RNA's P/S is 3.3x against a peer median of 14.7x; its net margin is -180.9% against a peer median of 0.0%.
Which of Atrium Therapeutics, Inc. Common Stock's competitors pays a higher dividend?
Atrium Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Atrium Therapeutics, Inc. Common Stock bigger than its competitors?
No. Atrium Therapeutics, Inc. Common Stock is 6th by market cap among the 13 companies on this page; the largest is SAB Biotherapeutics (SABS) at $266.66M.
RNA pages: Overview, Earnings, Forecast, Financials, Competitors